Growth Strategy

Our Three Pillars

Our growth strategy has three pillars to support future growth opportunities for our company.

1

Organic Growth of Current Portfolio

Drive organic growth by leveraging our existing product portfolio.

2

Business Development

License and/or acquire new products to fill our product pipeline and optimize our commercial infrastructure. The company is well capitalized to execute this growth strategy.

3

Product Development

Leverage our expertise within the areas of rheumatology and oncology to develop late stage products and or repurpose current drugs to expand our portfolio and enhance patients’ lives.

Licensing Targets

Licensing Targets

We continuously look to license or acquire new products and solutions aimed at addressing the essential needs of consumers, patients and health care partners, leveraging our North American sales force and infrastructure.

Canada

  • Rheumatology/Auto-immune disease
  • Specialty Oncology
  • Pediatrics
  • Allergy
  • Dermatology

USA

  • Rheumatology/Auto-immune disease
  • Specialty Oncology
Our Divisions

Our Divisions

We operate through two segments: Medexus Pharma Canada and Medexus Pharma USA. We have excellent coverage of rheumatologists in the USA and Canada, plus coverage of pediatrics, allergy and primary care in Canada.

View Divisions
Product Portfolio

Product Portfolio

Our highly diversified product portfolio and growing pipeline features several leading products such as Rasuvo, Metoject, Rupall, Treosulfan, and Gliolan. The majority of our portfolio is in growth phase.

View Product Portfolio